Common Comorbid Condition of Patients With Autism Spectrum Disorder and Pharmacotherapy for Patients With Autism Spectrum Disorder

다국어 초록 (Multilingual Abstract)

This article describes common comorbid condtion of the autism spectrum disorder (ASD) and recommends treatment guidelines of pharmacotherapy for patients with ASD. More than 95% of people with ASD have at least one additional disorder and guidelines how to evaluate and treat comorbid conditions in patients with ASD and 7 recommendations for treatment with medication for ASD.

참고문헌 (Reference)

1 American Psychiatric Association, "What is autism spectrum disorder?" American Psychiatric Association

2 Williams K, "Selective serotonin reuptake inhibitors(SSRIs)for autism spectrum disorders(ASD)" 8 : CD004677-, 2013

3 Aman MG, "Safety and efficacy of memantine in children with autism : randomized, placebo-controlled study and openlabel extension" 27 : 403-412, 2017

4 McDougle CJ, "Risperidone for the core symptom domains of autism : results from the study by the autism network of the research units on pediatric psychopharmacology" 162 : 1142-1148, 2005

5 Kent JM, "Risperidone dosing in children and adolescents with autistic disorder : a double-blind, placebo-controlled study" 43 : 1773-1783, 2013

6 Research Units on Pediatric Psychopharmacology Autism Network, "Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity" 62 : 1266-1274, 2005

7 Lai MC, "Prevalence of co-occurring mental health diagnoses in the autism population : a systematic review and meta-analysis" 6 : 819-829, 2019

8 Soke GN, "Prevalence of co-occurring medical and behavioral conditions/symptoms among 4-and 8-year-old children with autism spectrum disorder in selected areas of the United States in 2010" 48 : 2663-2676, 2018

9 Christensen DL, "Prevalence and characteristics of autism spectrum disorder among children aged 8 years — autism and developmental disabilities monitoring network, 11 sites, United States, 2012" 65 : 1-23, 2018

10 Volkmar F, "Practice parameter for the assessment and treatment of children and adolescents with autism spectrum disorder" 53 : 237-257, 2014

11 Wong HH, "Patterns of complementary and alternative medical therapy use in children diagnosed with autism spectrum disorders" 36 : 901-909, 2006

12 Ooi YP, "Oxytocin and autism spectrum disorders : a systematic review and meta-analysis of randomized controlled trials" 50 : 5-13, 2017

13 Sturman N, "Methylphenidate for children and adolescents with autism spectrum disorder" 11 : CD011144-, 2017

14 Williams KJ, "Intravenous secretin for autism spectrum disorders(ASD)" 2012 : CD003495-, 2012

15 Parker KJ, "Intranasal oxytocin treatment for social deficits and biomarkers of response in children with autism" 114 : 8119-8124, 2017

16 U.S. Food and Drug Administration, "Highlights of prescribing information: Risperidone" U.S. Food and Drug Administration

17 European Medicines Agency, "Haloperidol" European Medicines Agency

18 Scahill L, "Extended-release guanfacine for hyperactivity in children with autism spectrum disorder" 172 : 1197-1206, 2015

19 Reichow B, "Evidencebased practices and treatments for children with autism" Springer 2011

20 Hyman SL, "Evidence-based practices and treatments for children with autism" Springer 275-293, 2011

21 Fuentes J, "ESCAP practice guidance for autism : a summary of evidence-based recommendations for diagnosis and treatment" 30 : 961-984, 2021

22 U.S. Food and Drug Administration, "Drugs@FDA: FDA-approved drugs: Aripiprazole (products on NDA 021436)" U.S. Food and Drug Administration

23 Hollander E, "Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders" 35 : 990-998, 2010

24 Cortesi F, "Controlled-release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders : a randomized placebo-controlled trial" 21 : 700-709, 2012

25 Leyfer OT, "Comorbid psychiatric disorders in children with autism : interview development and rates of disorders" 36 : 849-861, 2006

26 Rosen TE, "Co-occurring psychiatric conditions in autism spectrum disorder" 30 : 40-61, 2018

27 Jaselskis CA, "Clonidine treatment of hyperactive and impulsive children with autistic disorder" 12 : 322-327, 1992

28 New York State Department of Health, "Clinical practice guideline on assessment and intervention services for young children with autism spectrum disorders (ASD)" New York State Department of Health

29 Fombonne E, "Beliefs in vaccine as causes of autism among SPARK cohort caregivers" 38 : 1794-1803, 2020

30 Bernaerts S, "Behavioral effects of multiple-dose oxytocin treatment in autism : a randomized, placebo-controlled trial with long-term follow-up" 11 : 6-, 2020

31 National Institute for Health and Care Excellence, "Autism: The management and support of children and young people on the autism spectrum: NICE guideline DRAFT" National Institute for Health and Care Excellence

32 National Institute for Health and Care Excellence, "Autism spectrum disorder in under 19s: support and management" National Institute for Health and Care Excellence

33 National Institute for Health and Care Excellence, "Autism spectrum disorder in adults: diagnosis and management" National Institute for Health and Care Excellence

34 Centers for Disease Control and Prevention, "Autism spectrum disorder (ASD). Recommendations and guidelines" Centers for Disease Control and Prevention

35 Ichikawa H, "Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan : a randomized, double-blind, placebo-controlled study" 48 : 796-806, 2017

36 Kim HW, "Aripiprazole for irritability in asian children and adolescents with autistic disorder : a 12-week, multinational, multicenter, prospective open-label study" 28 : 402-408, 2018

37 Goel R, "An update on pharmacotherapy of autism spectrum disorder in children and adolescents" 30 : 78-95, 2018

38 Mason D, "A systematic review of what barriers and facilitators prevent and enable physical healthcare services access for autistic adults" 49 : 3387-3400, 2019

39 Minshawi NF, "A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders" 7 : 2-, 2016

40 Wink LK, "A randomized placebo-controlled pilot study of N-acetylcysteine in youth with autism spectrum disorder" 7 : 26-, 2016

41 Harfterkamp M, "A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder" 51 : 733-741, 2012

42 Dean OM, "A randomised, double blind, placebo-controlled trial of a fixed dose of N-acetyl cysteine in children with autistic disorder" 51 : 241-249, 2017

43 Marcus RN, "A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder" 48 : 1110-1119, 2009

44 Hellings JA, "A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders" 15 : 682-692, 2005

45 Fankhauser MP, "A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism" 53 : 77-82, 1992